dc.contributor.author | Flobak, Åsmund | |
dc.contributor.author | Skånland, Sigrid S | |
dc.contributor.author | Hovig, Eivind | |
dc.contributor.author | Tasken, Kjetil | |
dc.contributor.author | Russnes, Hege Elisabeth Giercksky | |
dc.date.accessioned | 2023-01-06T09:09:28Z | |
dc.date.available | 2023-01-06T09:09:28Z | |
dc.date.created | 2022-11-10T10:20:33Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | TIPS - Trends in Pharmacological Sciences. 2022, 43 (11), 973-985. | en_US |
dc.identifier.issn | 0165-6147 | |
dc.identifier.uri | https://hdl.handle.net/11250/3041443 | |
dc.description.abstract | Functional precision medicine is a new, emerging area that can guide cancer treatment by capturing information from direct perturbations of tumor-derived, living cells, such as by drug sensitivity screening. Precision cancer medicine as currently implemented in clinical practice has been driven by genomics, and current molecular tumor boards rely extensively on genomic characterization to advise on therapeutic interventions. However, genomic biomarkers can only guide treatment decisions for a fraction of the patients. In this review we provide an overview of the current state of functional precision medicine, highlight advances for drug-sensitivity screening enabled by cell culture models, and discuss how artificial intelligence (AI) can be coupled to functional precision medicine to guide patient stratification. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models | en_US |
dc.title.alternative | Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | acceptedVersion | en_US |
dc.source.pagenumber | 973-985 | en_US |
dc.source.volume | 43 | en_US |
dc.source.journal | TIPS - Trends in Pharmacological Sciences | en_US |
dc.source.issue | 11 | en_US |
dc.identifier.doi | 10.1016/j.tips.2022.08.009 | |
dc.identifier.cristin | 2071602 | |
dc.relation.project | Norges forskningsråd: 310160 | en_US |
dc.relation.project | Norges forskningsråd: 294916 | en_US |
dc.relation.project | Norges forskningsråd: 328827 | en_US |
dc.relation.project | Norges forskningsråd: 322898 | en_US |
dc.relation.project | Kreftforeningen: 215850 | en_US |
dc.relation.project | Helse Sør-Øst RHF: 2019057 | en_US |
dc.relation.project | Helse Sør-Øst RHF: 2021082 | en_US |
dc.relation.project | Norges forskningsråd: 315538 | en_US |
dc.relation.project | Norges forskningsråd: 329059 | en_US |
cristin.ispublished | true | |
cristin.fulltext | postprint | |
cristin.qualitycode | 1 | |